placeholder
Importance
62
Trust
70
Urgency
30
REGULATORY · PRIMARY SOURCE
Medica Weight Loss - 728284 - 06/08/2026
The FDA warned Medica Weight Loss for making false claims about compounded semaglutide and tirzepatide on its website. The company falsely claimed the drugs were FDA-approved and sourced from an 'FDA-approved pharmacy'—neither statement is legal for compounded drugs.
Analysis
FDA keeps cracking down on clinics selling compounded semaglutide and tirzepatide with false claims. This pushes patients toward brand-name Ozempic and Zepbound.
- FDA warned Medica Weight Loss (Aventura, FL) on June 8, 2026 for false claims about compounded semaglutide and tirzepatide
- Website falsely claimed compounded drugs were 'FDA-approved' and sourced from an 'FDA-approved pharmacy'
- Medica must respond in writing within 15 business days or face seizure and injunction
FDA Drug Approvals & Databases4d
Read